Last reviewed · How we verify
PM02734 and erlotinib — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PM02734 and erlotinib (PM02734 and erlotinib) — PharmaMar.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PM02734 and erlotinib TARGET | PM02734 and erlotinib | PharmaMar | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PM02734 and erlotinib CI watch — RSS
- PM02734 and erlotinib CI watch — Atom
- PM02734 and erlotinib CI watch — JSON
- PM02734 and erlotinib alone — RSS
Cite this brief
Drug Landscape (2026). PM02734 and erlotinib — Competitive Intelligence Brief. https://druglandscape.com/ci/pm02734-and-erlotinib. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab